Here are the 10-K annual reports from Equillium, Inc. (EQ) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow EQ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EQ filings page.
Equillium, Inc. files its annual report describing a preclinical-stage biotechnology business focused on therapies for severe autoimmune and inflammatory disorders. The company’s lead program, EQ504, is an aryl hydrocarbon receptor modulator initially targeted for ulcerative colitis and other gastrointestinal and inflammatory lung diseases.
EQ302 is a first-in-class, orally delivered inhibitor of IL‑15 and IL‑21 being evaluated for celiac disease and other gastrointestinal indications. Equillium expanded its pipeline through acquiring Ariagen in October 2024 for EQ504 and Bioniz in February 2022 for EQ302 and related peptide platforms.
The company strengthened its balance sheet via an August 2025 private placement raising approximately $30.0 million and a March 2026 private placement raising approximately $35.0 million, with an additional potential $20.0 million second closing tied to clinical and stock price milestones. Management states existing cash and cash equivalents are expected to fund operations into 2029.